Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Primary Endpoint Miss (new) — Lead drug candidate failed to meet primary success measure in pivotal Phase 2/3 trial
- Enrollment Pause (new) — Company halted second trial to reassess program, signaling uncertainty about path forward
Praxis halts vormatrigine trial enrollment after Phase 2/3 study misses primary endpoint
Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
high
POWER1 Phase 2/3 trial in focal onset seizures failed primary endpoint, though secondary 50% response rate was met and higher doses showed more seizure reduction in second half of study
Item 8.01 verify on EDGAR → -
high
Company paused enrollment in POWER2 trial to reassess vormatrigine program and determine potential modifications to clinical strategy
Item 8.01 verify on EDGAR → -
medium
Drug was generally well-tolerated with under 10% discontinuations due to adverse events; approximately 90% of vormatrigine patients transitioned to open-label extension study
Item 8.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GIS 10-K) is open in full — no account needed.
Partner
Trade PRAX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jul 3, 2026 12:38 AM